Greylin Investment Mangement Inc. raised its stake in shares of Pfizer Inc. (NYSE:PFE) by 2.5% in the fourth quarter, according to its most recent 13F filing with the SEC. The fund owned 58,388 shares of the biopharmaceutical company’s stock after purchasing an additional 1,440 shares during the period. Greylin Investment Mangement Inc.’s holdings in Pfizer were worth $2,115,000 as of its most recent SEC filing.
A number of other hedge funds also recently added to or reduced their stakes in PFE. Investment Centers of America Inc. boosted its stake in shares of Pfizer by 2.3% in the 3rd quarter. Investment Centers of America Inc. now owns 195,611 shares of the biopharmaceutical company’s stock worth $6,990,000 after buying an additional 4,472 shares during the last quarter. Meag Munich Ergo Kapitalanlagegesellschaft MBH raised its holdings in shares of Pfizer by 437.9% in the 3rd quarter. Meag Munich Ergo Kapitalanlagegesellschaft MBH now owns 773,073 shares of the biopharmaceutical company’s stock worth $27,607,000 after purchasing an additional 629,361 shares during the period. Stanley Laman Group Ltd. raised its holdings in shares of Pfizer by 373.7% in the 2nd quarter. Stanley Laman Group Ltd. now owns 114,284 shares of the biopharmaceutical company’s stock worth $3,839,000 after purchasing an additional 90,160 shares during the period. Atlantic Trust LLC raised its holdings in shares of Pfizer by 19.8% in the 2nd quarter. Atlantic Trust LLC now owns 27,400 shares of the biopharmaceutical company’s stock worth $748,000 after purchasing an additional 4,530 shares during the period. Finally, ProVise Management Group LLC raised its holdings in shares of Pfizer by 5.9% in the 2nd quarter. ProVise Management Group LLC now owns 244,076 shares of the biopharmaceutical company’s stock worth $8,198,000 after purchasing an additional 13,616 shares during the period. Institutional investors and hedge funds own 71.41% of the company’s stock.
A number of equities research analysts recently commented on the stock. Sanford C. Bernstein set a $43.00 price target on shares of Pfizer and gave the stock a “buy” rating in a report on Tuesday, January 30th. Goldman Sachs Group set a $36.00 price target on shares of Pfizer and gave the stock a “neutral” rating in a report on Tuesday, January 30th. UBS Group set a $42.00 price target on shares of Pfizer and gave the stock a “buy” rating in a report on Wednesday, January 31st. BMO Capital Markets set a $39.00 price target on shares of Pfizer and gave the stock a “buy” rating in a report on Tuesday, January 30th. Finally, Deutsche Bank set a $38.00 price target on shares of Pfizer and gave the stock a “buy” rating in a report on Wednesday, December 6th. Two equities research analysts have rated the stock with a sell rating, ten have given a hold rating and eleven have given a buy rating to the company’s stock. The company currently has a consensus rating of “Hold” and a consensus price target of $39.40.
Shares of Pfizer Inc. (NYSE PFE) opened at $36.75 on Wednesday. The company has a current ratio of 1.35, a quick ratio of 1.10 and a debt-to-equity ratio of 0.47. Pfizer Inc. has a 1-year low of $31.67 and a 1-year high of $39.43. The stock has a market cap of $218,770.00, a price-to-earnings ratio of 21.00, a price-to-earnings-growth ratio of 2.07 and a beta of 0.91.
Pfizer (NYSE:PFE) last issued its earnings results on Tuesday, January 30th. The biopharmaceutical company reported $0.62 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.56 by $0.06. Pfizer had a net margin of 40.55% and a return on equity of 25.21%. The business had revenue of $13.70 billion for the quarter, compared to analysts’ expectations of $13.67 billion. During the same quarter in the previous year, the firm posted $0.47 EPS. The business’s revenue for the quarter was up .6% compared to the same quarter last year. equities research analysts forecast that Pfizer Inc. will post 2.95 earnings per share for the current fiscal year.
The company also recently declared a quarterly dividend, which was paid on Thursday, March 1st. Stockholders of record on Friday, February 2nd were issued a $0.34 dividend. The ex-dividend date of this dividend was Thursday, February 1st. This represents a $1.36 annualized dividend and a dividend yield of 3.70%. This is a boost from Pfizer’s previous quarterly dividend of $0.32. Pfizer’s dividend payout ratio is presently 77.71%.
Pfizer declared that its board has authorized a stock repurchase program on Monday, December 18th that permits the company to repurchase $10.00 billion in outstanding shares. This repurchase authorization permits the biopharmaceutical company to buy shares of its stock through open market purchases. Shares repurchase programs are usually an indication that the company’s board believes its stock is undervalued.
WARNING: This story was originally posted by American Banking News and is the property of of American Banking News. If you are reading this story on another site, it was stolen and republished in violation of U.S. & international trademark & copyright laws. The original version of this story can be viewed at https://www.americanbankingnews.com/2018/03/14/greylin-investment-mangement-inc-has-2-12-million-holdings-in-pfizer-inc-pfe.html.
Pfizer Inc (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines, as well as consumer healthcare products. The Company manages its commercial operations through two business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH).
Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE).
Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.